Aspirin therapy in vernal conjunctivitis.
Prostaglandin D2 is a secondary mast cell mediator that causes redness, chemosis, mucous discharge, and eosinophil chemotaxis in the eye. It may play an important role in allergic ocular disease. Although histamine is a key mediator of allergic inflammation, antihistamine therapy provides only symptomatic relief. We added aspirin therapy to the treatment regimen of three patients with vernal conjunctivitis. Aspirin acetylates the enzyme cyclooxygenase, thereby preventing the formation of prostaglandin D2. Within two weeks after initiation of aspirin therapy, we noted dramatic improvement in conjunctival and episcleral redness and resolution of keratitis and limbal infiltration. We recommend a trial of oral aspirin as adjunctive therapy for intractable cases of vernal conjunctivitis.
D000293:Adolescent; D001241:Aspirin / Q000627:therapeutic use*; D002648:Child; D003231:Conjunctivitis / Q000188:drug therapy*; D005260:Female; D006632:Histamine / Q000502:physiology; D006801:Humans; D006967:Hypersensitivity / Q000150:complications*; D008297:Male; D008407:Mast Cells / Q000502:physiology; D015230:Prostaglandin D2; D011457:Prostaglandins D / Q000502:physiology; D012621:Seasons; D014582:Urticaria Pigmentosa / Q000188:drug therapy
D011457:Prostaglandins D; D006632:Histamine; D001241:Aspirin; D015230:Prostaglandin D2